APRIL
11.4.2024 11:59:30 CEST | Business Wire | Press release
Building on the success of its first transformation plan, APRIL is embarking on a new phase in its development with the ambition of becoming a European leader of global stature in the design, distribution and management of insurance solutions and financial products. The Group is planning an ambitious growth cycle, both organic and external, which will take it to a turnover of more than €1 billion by 2027.
With sales of €630m by 2023, 20% of which will be generated outside France, the Spring 2023 strategic plan has enabled APRIL to return to its basics and achieve sustainable growth. Today, the Group is looking ahead to a new stage in its development and has set itself the target of exceeding €1 billion in turnover by 2027.
« In an extremely competitive international environment, one of the most successful insurance brokers is French! Our nearly 3,000 employees are proud to continue APRIL's history and are in action to expand our global footprint, for the benefit of our tens of thousands of partners and our millions of customers, whom we support and protect on a daily basis, » states Eric Maumy, CEO of APRIL.
Four cardinal points to guide the Group's development:
the spirit of conquest, customer delight, technological performance and talent.
The spirit of conquest to become a global consolidator
With its sustained growth, APRIL Group will further accelerate its development based on three principles:
- Organic growth in its traditional markets: health and personal insurance for individuals, professionals and businesses, health insurance for expatriates and property and casualty insurance (auto, 2-wheeler, construction, real estate and yachting).
- Diversification into new growth drivers, as the Group has already begun to do with savings and asset management, which have become the Group's 4th business line.
- Internationalisation in all its markets, starting with international health, with strong ambitions in Europe, the Middle East and Asia.
In terms of diversification and internationalisation, APRIL Group intends to step up its external growth momentum, as demonstrated by the two deals completed since the beginning of 2024 with leading French savings company DLPK and UK two-wheeler specialist Lexham Insurance.
This consolidation drive will naturally go hand in hand with APRIL’s ongoing commitment to defending the interests of customers, particularly in terms of access to quality healthcare for as many people as possible.
Enchanting partners and customers to reinvent the insurance experience
Having improved its Net Promoter Score by more than 20 points in 4 years, the Group wants to accelerate its efforts to improve the experience of its partners and customers, by focusing on 3 key areas:
- Enhancing its service approach (easier access to healthcare networks and to teleconsultation facilities, etc.);
- Improving its digital systems - from the underwriting process to self-care areas and conversational tools;
- Strengthening and continually training the teams in contact with customers and partners, to offer them the very best in technology and human relations.
A technological transformation that incorporates Data & AI
APRIL Group plans to invests €70 million in its digital and technological transformation by 2027 with a twofold aim :
- Capitalising on data and artificial intelligence, via iterative projects that will be carried out within the group in France and internationally across all business lines to identify the potential for creating value for employees, customers and partners;
- Continuing to strengthen cyber security in an environment of heightened threat to all economic players.
Providing employees with a unique experience to attract and retain talent
With an average of 400 new hires per year since 2020, APRIL Group has strengthened its team, in particular by recruiting talent in high-tension professions, notably digital technology within its APRIL X hub and customer relations.
With its ambitions raised to 2027, the Group plans to offer a structured and enriched employee experience based on 3 levers:
- Developing talent through the knowledge factory, which will include strengthening the APRIL University and launching an Apprentice Training Centre;
- Focusing on our employees, with several agreements on intergenerational dynamics and inclusion & diversity, as well as the relocation of the Group's head office to more modern, collaborative offices in Lyon (France);
- Greater sharing of value, with the opening of the capital to all the Group's employees worldwide from April 2024.
True to its roots in the social economy, the Group plans to fuel its sustainable growth with a positive and real impact in terms of CSR, in particular through its APRIL Foundation, which focuses on the contribution of behavioural sciences to health prevention and promotion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411952024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
